A New Therapeutic Target for Treatment of Cancer: High Mobility Group Box 1 Protein

被引：0

作者：

Yildirim, Mustafa ^{[1
]}

Kaya, Vildan ^{[2
]}

Suren, Dinc ^{[3
]}

机构：

[1] Batman Bolge Devlet Hastanesi, Med Onkol Klin, Batman, Turkey

[2] Suleyman Demirel Univ, Tip Fak, Radyasyon Onkol AD, TR-32200 Isparta, Turkey

[3] Antalya Egitim Arastirma Hastanesi, Patol Klin, Antalya, Turkey

来源：

JOURNAL OF CLINICAL AND ANALYTICAL MEDICINE | 2015年 / 6卷 / 04期

关键词：

High Mobility Group Box; Cancer; Targeted Therapy;

D O I：

10.4328/JCAM.2138

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

High mobility group box proteins are non-histon nuclear proteins which have many different functions in the cell. High mobility group box 1 is the most important member of this family. Its overexpression is showed that many cancer types such as hepatocellular carcinoma, squamous cell skin cancer, prostate cancer, gastrointestinal cancer, breast cancer, acute myeloid leukemia. Many studies suggest that HMGB1 may have an important role in the development of cancer. Therefore, HMGB1 and it's receptor RAGE is becoming an important therapeutic target. In this review, HMGB1 targeted therapies are discussed because it is a new therapeutic target in cancer.

引用

页码：534 / 536

页数：3

共 31 条

[1] High mobility group box1 (HMGB1) in relation to cutaneous inflammation in systemic lupus erythematosus (SLE)
Abdulahad, D. A.
Westra, J.
Reefman, E.
Zuidersma, E.
Bijzet, J.
Limburg, P. C.
Kallenberg, C. G. M.
Bijl, M.
[J]. LUPUS, 2013, 22 (06) : 597 - 606
[2] Antisense Treatment in Human Prostate Cancer and Melanoma
Di Cresce, C.
Koropatnick, J.
[J]. CURRENT CANCER DRUG TARGETS, 2010, 10 (06) : 555 - 565
[3] Quercetin decreases oxidative stress, NF-κB activation, and iNOS overexpression in liver of streptozotocin-induced diabetic rats
Dias, Alexandre Simoes
Porawski, Marilene
Alonso, Maria
Marroni, Norma
Collado, Pilar S.
Gonzalez-Gallego, Javier
[J]. JOURNAL OF NUTRITION, 2005, 135 (10) : 2299 - 2304
[4] High mobility group box I (HMGB1) release from tumor cells after treatment: Implications for development of targeted chemoimmunotherapy
Dong, Xiang Da
Ito, Norimasa
Lotze, Michael T.
DeMarco, Richard A.
Popovic, Petar
Shand, Stuart H.
Watkins, Simon
Winikoff, Stephen
Brown, Charles K.
Bartlett, David L.
Zeh, Herbert J., III
[J]. JOURNAL OF IMMUNOTHERAPY, 2007, 30 (06) : 596 - 606
[5] Masquerader: High mobility group box-1 and cancer
Ellerman, Jessica E.
Brown, Charles K.
de Vera, Michael
Zeh, Herbert J.
Billiar, Timothy
Rubartelli, Anna
Lotze, Michael T.
[J]. CLINICAL CANCER RESEARCH, 2007, 13 (10) : 2836 - 2848
[6] Short hairpin RNA (shRNA) constructs targeting high mobility group box-1 (HMGB1) expression leads to inhibition of prostate cancer cell survival and apoptosis
Gnanasekar, Munirathinam
Thirugnanam, Sivasakthivel
Ramaswamy, Kalyanasundaram
[J]. INTERNATIONAL JOURNAL OF ONCOLOGY, 2009, 34 (02) : 425 - 431
[7] Gene Silencing by Gold Nanoshell-Mediated Delivery and Laser-Triggered Release of Antisense Oligonucleotide and siRNA
Huschka, Ryan
Barhoumi, Aoune
Liu, Qing
Roth, Jack A.
Ji, Lin
Halas, Naomi J.
[J]. ACS NANO, 2012, 6 (09) : 7681 - 7691
[8] Non-histone nuclear factor HMGB1 is phosphorylated and secreted in colon cancers
Kang, Hyun Ju
Lee, Hanna
Choi, Hee-Jung
Youn, Ju Ho
Shin, Jeon-Soo
Ahn, Yeong Hee
Yoo, Jong Shin
Paik, Young-Ki
Kim, Hoguen
[J]. LABORATORY INVESTIGATION, 2009, 89 (08) : 948 - 959
[9] The expression of HMGB1 protein and its receptor RAGE in human malignant tumors
Kostova, Nora
Zlateva, Stanislava
Ugrinova, Iva
Pasheva, Evdokia
[J]. MOLECULAR AND CELLULAR BIOCHEMISTRY, 2010, 337 (1-2) : 251 - 258
[10] Chromatin-associated proteins HMGB1/2 and PDIA3 trigger cellular response to chemotherapy-induced DNA damage
Krynetskaia, Natalia F.
Phadke, Manali S.
Jadhav, Sachin H.
Krynetskiy, Evgeny Y.
[J]. MOLECULAR CANCER THERAPEUTICS, 2009, 8 (04) : 864 - 872

← 1 2 3 4 →